摘要
目的研究奥扎格雷对急性冠脉综合征(ACS)患者血浆血管性血友病因子(vWF)含量及基质金属蛋白酶-9(MMP-9)水平的影响。方法选择84例ACS患者,随机分为对照组(常规治疗,n=42)和治疗组(常规治疗加奥扎格雷,n=42),测定治疗前后患者血浆vWF含量及MMP-9水平,同时比较治疗前后心电图改善情况,并进行统计分析。结果 2组患者治疗后的血浆vWF及MMP-9水平均呈显著下降的趋势,其中治疗组血浆vWF及MMP-9水平下降的幅度均显著大于对照组。结论采用奥扎格雷治疗ACS患者,可显著降低血浆vWF含量及MMP-9水平。
Objective To explore the influence of ozagrel on levels of plasma von willebrand factor（vWF） and metalloprotease-9 （MMP-9）in patients with acute coronary syndrome （ACS）. Methods 84 ACS patients were divided into control group（conventional treatment, n = 42） and treatment group（conventional treatment plus ozagrel, n = 42）. Levels of plasma vWF and MMP-9 before and after treatment were detected, and meanwhile electrocardiogram condition before and af- ter treatment were compared and analyzed. Results The levels of plasma vWF and MMP-9 in both of two groups reduced significantly, and the declined extent of vWF and MMP-9 in treatment group were significantly larger than the control group （P 〈 0.05）. Conclusion With the treatment of ozagrel for patients with ACS, the levels of plasma vWF and MMP-9 can be reduced remarkably
出处
《实用临床医药杂志》
CAS
2012年第23期49-50,53,共3页
Journal of Clinical Medicine in Practice
